Opinions Lou Schizas
Medmira IncMIR.VDON'T BUYJul 04, 2003
Got approval from FDA, but sales are not following through. Running out of cash. Any new financing could dilute stock price further.
Lou SchizasUnknown
$1.29
Stock price when the opinion was issued
$0.06
As of Jun 03, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentTOP PICK
In Canada, this smallcap (C$210 million) biotech in Halifax submitted its antibody test to the FDA. Since April 22, MedMira has soared from 6 cents/share to over 30. There's scant coverage or even stock metrics to report. Also MedMira is one of many companies to submit such tests to the FDA, but it's worth keeping on your radar. At this stage of pandemic, I wouldn't rule out any stock that could effectively fight the virus.
biotechnologypharmaceutical
